
XNK Therapeutics AB announced today that Evencaleucel had received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). The recommendation classifies evencaleucel as a Somatic Cell Therapy Medicinal Product (sCTMP) within the category of Advanced Therapy Medicinal Products (ATMPs). XNK's manufacturing platform for evencaleucel is well-suited for developing autologous NK cell-based drug candidates to target malignant diseases in mono- and combination therapy. This milestone marks a crucial step in XNK's regulatory approval journey, facilitating future interactions with authorities. Peter Hovstadius, XNK's Chief Medical Officer, expressed satisfaction with the EMA's scientific recommendation.
Like
Save
Share